The Seattle Cancer Care Alliance (SCCA), located in Seattle, Washington, is part of a dynamic collaboration among three organizations known nationally and internationally for their patient care and research: Fred Hutchinson Cancer Research Center, University of Washington, and Seattle Children's. Over the past 25 years, these institutions have worked together to support their mission of adult and pediatric oncology patient care services, research and education.
The Cellular Therapy Lab (CTL) at the Seattle Cancer Care Alliance (SCCA) is on the cutting edge of new technologies for cancer therapy, including cell-based immunotherapy. We are committed to advancing treatment options for our patients through the translation of innovative research into clinical practice. We collaborate with our Alliance partners (University of Washington, Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital) as well as industry (biotechnology) and non-industry external entities.
CTL is responsible for all minimally manipulated therapeutic cell processing occurring at the SCCA for standard therapies, clinical trials and commercial cell therapeutics. Procedures range from cryopreservation to flow cytometric enumeration of cell proportions to more complex procedures such as cell selections, including enrichment and depletion. The laboratory is regulated by the FDA cGTP/cGMP standards, maintains College of American Pathologists (CAP) certification, and is accredited by the Joint Commission and FACT.
Employees must adhere to all SCCA policies and processes, including the SCCA Code of Conduct and all HIPAA privacy requirements.